Nano drug delivery systems for ovarian cancer therapy

Ovarian cancer is the second most common gynecologic cancer in Europe and the USA, and the most fatal gynecologic malignancy among all cancers with a mortality rate of 6%. The traditional treatment of ovarian cancer includes cytoreductive surgery and platinum-taxane combined chemotherapy. Although the response to the standard treatment scheme is promising at first, the disease often recurs and eventually treatment fails with the development of chemoresistance as the main cause of failure of treatment. The purpose of this brief review is to summarize the new strategies, especially in terms of nanotechnology, for the treatment of ovarian cancer.